211At-BC8-B10 / Fred Hutchinson Cancer Center - LARVOL DELTA

NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Fred Hutchinson Cancer Center | Trial primary completion date: May 2024 ➔ Jun 2027

Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • Transplantation • HLA-B • HLA-DRB1

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Fred Hutchinson Cancer Center | Suspended ➔ Recruiting

Enrollment open • Oncology • HLA-A • HLA-B • HLA-C • HLA-DQB1 • HLA-DRB1

NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Fred Hutchinson Cancer Center | Trial primary completion date: Jun 2027 ➔ May 2024

Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • Transplantation • HLA-B • HLA-DRB1

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (clinicaltrials.gov) - P1/2 | N=75 | Recruiting | Sponsor: Fred Hutchinson Cancer Center | Suspended ➔ Recruiting | Trial completion date: Mar 2027 ➔ Mar 2029 | Trial primary completion date: Jan 2023 ➔ Jun 2027

Enrollment open • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • Transplantation • HLA-B • HLA-C • HLA-DQB1 • HLA-DRB1

NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Fred Hutchinson Cancer Center | Trial completion date: Mar 2027 ➔ Mar 2029 | Trial primary completion date: Jun 2025 ➔ Jun 2027

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • Transplantation • HLA-B • HLA-DRB1

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases (clinicaltrials.gov) - P1/2 | N=40 | Suspended | Sponsor: Fred Hutchinson Cancer Center | Recruiting ➔ Suspended

Trial suspension • Oncology • HLA-A • HLA-B • HLA-C • HLA-DQB1 • HLA-DRB1

NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Fred Hutchinson Cancer Center | Trial completion date: Oct 2025 ➔ Mar 2027 | Trial primary completion date: Jan 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • Transplantation • HLA-B • HLA-DRB1